Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2006

View Archived Issues

Preclinical and clinical results for ceftaroline reported at ICAAC

Hsp90 inhibition activates Fas apoptotic pathway in cultured motor neurons

Talabostat upregulates innate and acquired immunity against cancer cells

Phase I/II study of Cardeva begins dosing

Indian approval for glioblastoma trial of Cotara

Endo acquires RxKinetix

FDA requests additional data to support use of Fuzeon with needle-free device

Enrollment completed in skin cancer pilot study of PEP-005 Topical

TPM-02/insulin delivers insulin through skin in phase I trial

Gene Logic to seek alternative development paths for Lilly drug candidates

Ambrilia licenses HIV/AIDS protease inhibitor program rights to Merck & Co.

End-of-phase II meeting requested for Diamyd

SPA reached for phase II study of M-Vax in metastatic melanoma

EKR Therapeutics acquires North American rights for Gelclair

Dosing completed in twin phase III studies of PreHistin

Fresenius to acquire phosphate binder business from Nabi

Multispan and Medarex sign licensing agreement

Immune Response updates recent clinical progress

Recent patents disclose novel antiinfective agents

Recent Novartis and GSK patents impart new therapeutics for respiratory disorders

New agents for depression, psychosis, sleep disorders, etc., patented

AMG-517, a novel TRPV1 antagonist, from Amgen

SCH-697466: a novel gamma-secretase inhibitor profiled at the SfN meeting

Abbott and Icagen present a potent and selective Nav1.8 blocker with analgesic efficacy

Orphan drug designation for talactoferrin in renal cell carcinoma

Aricept approved for severe Alzheimer's disease

French approval for Loramyc for oropharyngeal candidiasis

Wyeth presents the neuroprotective effects of novel Src kinase inhibitor in stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
SERCA inhibitor shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...